Clinical Trial Update: A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a combination of cladribine, low-dose cytarabine, and venetoclax for relapsed/refractory or secondary acute myeloid leukemia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Cladribine (cladribine)
• Low-dose cytarabine (Cytarabine (low-dose))
• Venetoclax (venetoclax)

Snippet

Sponsor: University of Rochester | Conditions: Acute Myeloid Leukemia (AML) | Phase 2 | Status: NOT_YET_RECRUITING